New York City hospitals are dropping Palantir's AI systems even as the controversial data analytics firm expands its healthcare presence in the United Kingdom. The timing raises an obvious question: what did NYC learn that the NHS hasn't?
Palantir has always been a polarizing company. Founded with CIA funding and built on contracts with defense and intelligence agencies, the company has spent the past decade trying to diversify into commercial and healthcare markets. Their pitch: the same data integration technology that tracks terrorists can optimize hospital operations.
NYC apparently isn't convinced anymore.
What went wrong in New York
According to reporting from The Guardian, several major NYC hospital systems are ending contracts with Palantir after trials that revealed more problems than solutions. Specific issues included:
• Integration challenges: Hospital IT systems are notoriously complex, and Palantir's platform struggled to integrate with existing electronic health record systems • Cost concerns: The systems required extensive customization, driving costs far beyond initial estimates • Usability problems: Clinicians found the interfaces difficult to use in fast-paced hospital environments • Unclear value: The promised improvements in patient outcomes and operational efficiency didn't materialize in measurable ways
None of this is surprising to anyone familiar with enterprise healthcare IT. The sector is littered with expensive technology projects that promised transformation and delivered frustration. What's notable is that Palantir — a company that positions itself as elite-tier tech — ran into the same implementation problems as everyone else.
Meanwhile, in the UK...
While NYC backs away, Palantir is expanding its relationship with the UK's National Health Service. The company has secured contracts worth hundreds of millions of pounds to build data platforms and AI systems for the NHS.
The UK government's pitch is that Palantir's technology will help the NHS manage patient data more effectively, optimize resource allocation, and improve care coordination. Critics warn about handing sensitive healthcare data to a company with deep ties to intelligence agencies and a business model built on surveillance.
